Government-Owned Inventions; Availability for Licensing, 4573 [2010-1668]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 18 / Thursday, January 28, 2010 / Notices
Inventors: Peter D. Burbelo and
Michael J. Iadarola (NIDCR).
Related Publications:
1. Burbelo PD, Leahy HP, Issa AT,
Groot S, Baraniuk JN, Nikolov NP, Illei
GG, Iadarola MJ. Sensitive and robust
luminescent profiling of anti-La and
other autoantibodies in Sjogren’s
syndrome. Autoimmunity. 2009
Sep;42(6):515–524. [PubMed: 19657778]
2. Burbelo PD, Ching KH, Issa AT,
Loftus CM, Li Y, Satoh M, Reeves WH,
Iadarola MJ. Rapid serological detection
of autoantibodies associated with
¨
Sjogren’s syndrome. J Transl Med. 2009
Sep 24;7:83. [PubMed: 19778440]
3. Burbelo PD, Ching KH, Klimavicz
CM, Iadarola MJ. Antibody profiling by
Luciferase Immunoprecipitation
Systems (LIPS). J Vis Exp. 2009 Oct
7;(32); pii: 1549; doi: 10.3791/1549.
[PubMed: 19812534]
Patent Status: U.S. Provisional
Application No. 61/224,649 filed 10 Jul
2009 (HHS Reference No. E–070–2009/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Norbert Pontzer,
J.D., Ph.D.; 301–435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Dental and
Craniofacial Research, Laboratory of
Sensory Biology, Neurobiology and Pain
Therapeutics Section, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact David W. Bradley, Ph.D. at 301–
402–0540 or bradleyda@nidcr.nih.gov
for more information.
Dated: January 21, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–1680 Filed 1–27–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSKH9S0YB1PROD with NOTICES
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
VerDate Nov<24>2008
17:16 Jan 27, 2010
Jkt 220001
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone:
301/496–7057; fax: 301/402–0220. A
signed Confidential Disclosure
Agreement will be required to receive
copies of the patent applications.
Nitric Oxide-Based Therapeutics for
Lung Cancer
Description of Invention: JS–36–25, a
diazeniumdiolate prodrug, is available
for licensing and development of
treatments for lung cancer. The
inventors have demonstrated a potent
tumoristatic activity of JS–36–25 in both
lung cancer cells in vitro and as
xenografts in mice. JS–36–25 treatment
led to 85% reduction of tumor growth
in vivo. The tumoristatic potency of the
compound correlated well with the
level of endogenous reactive oxygen
species (ROS) in the cancer cells. Thus,
in addition to potent tumoristatic
activity when administered alone, this
compound is predicted to have a strong
synergy with therapeutics that act
through generation of ROS, such as
bortezomib, doxorubicin, as well as
high-energy radiation.
Applications: Development of lung
cancer treatments.
Development Status: Pre-clinical.
Market: There are over 160,000 new
cases of lung cancer every year in the
United States alone.
Inventors: Anna E. Maciag et al. (NCI).
Patent Status: U.S. Provisional
Application No. 61/261,175 filed 13
November 2009 (HHS Reference No.
E–025–2010/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Steve Standley,
Ph.D.; 301–435–4074;
sstand@od.nih.gov.
T-Cell-Specific Gfi-1 Knockout Mouse
Description of Invention: This is a
mouse model available to study T-cell
differentiation. Growth factor
independent 1 (GFi-1) is a
transcriptional repressor that is
transiently induced during T-cell
activation. This knockout mouse line is
a GFi-1[flox/flox] introduced into a
mouse Cre controlled by a CD4
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
4573
promoter, which allows selective
removal of GFi-1 exclusively in T-cells.
It has thus-far been used to demonstrate
that GFi-1 plays a critical role in
enhancing Th2 cell expansion and
repressing induction of Th17 and
CD103+ iTreg cells.
Applications: Tool for studying T-cell
proliferation and differentiation.
Inventors: Jinfang Zhu and William E.
Paul (NIAID).
Related Publication: J Zhu, TS
Davidson, G Wei, D Jankovic, K Cui, DE
Schones, L Guo, K Zhao, EM Shevach,
WE Paul. Down-regulation of Gfi-1
expression by TGF-beta is important for
differentiation of Th17 and CD103+
inducible regulatory T cells. J Exp Med.
2009 Feb 16;206(2):329–341. [PubMed:
19188499].
Patent Status: HHS Reference No.
E–242–2009/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Steve Standley,
Ph.D.; 301–435–4074;
sstand@od.noh.gov.
Dated: January 21, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–1668 Filed 1–27–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
E:\FR\FM\28JAN1.SGM
28JAN1
]]>Agencies
[Federal Register Volume 75, Number 18 (Thursday, January 28, 2010)]
[Notices]
[Page 4573]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-1668]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Nitric Oxide-Based Therapeutics for Lung Cancer
Description of Invention: JS-36-25, a diazeniumdiolate prodrug, is
available for licensing and development of treatments for lung cancer.
The inventors have demonstrated a potent tumoristatic activity of JS-
36-25 in both lung cancer cells in vitro and as xenografts in mice. JS-
36-25 treatment led to 85% reduction of tumor growth in vivo. The
tumoristatic potency of the compound correlated well with the level of
endogenous reactive oxygen species (ROS) in the cancer cells. Thus, in
addition to potent tumoristatic activity when administered alone, this
compound is predicted to have a strong synergy with therapeutics that
act through generation of ROS, such as bortezomib, doxorubicin, as well
as high-energy radiation.
Applications: Development of lung cancer treatments.
Development Status: Pre-clinical.
Market: There are over 160,000 new cases of lung cancer every year
in the United States alone.
Inventors: Anna E. Maciag et al. (NCI).
Patent Status: U.S. Provisional Application No. 61/261,175 filed 13
November 2009 (HHS Reference No. E-025-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Steve Standley, Ph.D.; 301-435-4074;
sstand@od.nih.gov.
T-Cell-Specific Gfi-1 Knockout Mouse
Description of Invention: This is a mouse model available to study
T-cell differentiation. Growth factor independent 1 (GFi-1) is a
transcriptional repressor that is transiently induced during T-cell
activation. This knockout mouse line is a GFi-1[flox/flox] introduced
into a mouse Cre controlled by a CD4 promoter, which allows selective
removal of GFi-1 exclusively in T-cells. It has thus-far been used to
demonstrate that GFi-1 plays a critical role in enhancing Th2 cell
expansion and repressing induction of Th17 and CD103+ iTreg cells.
Applications: Tool for studying T-cell proliferation and
differentiation.
Inventors: Jinfang Zhu and William E. Paul (NIAID).
Related Publication: J Zhu, TS Davidson, G Wei, D Jankovic, K Cui,
DE Schones, L Guo, K Zhao, EM Shevach, WE Paul. Down-regulation of Gfi-
1 expression by TGF-beta is important for differentiation of Th17 and
CD103+ inducible regulatory T cells. J Exp Med. 2009 Feb 16;206(2):329-
341. [PubMed: 19188499].
Patent Status: HHS Reference No. E-242-2009/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: This technology is available as a research tool
under a Biological Materials License.
Licensing Contact: Steve Standley, Ph.D.; 301-435-4074;
sstand@od.noh.gov.
Dated: January 21, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-1668 Filed 1-27-10; 8:45 am]
BILLING CODE 4140-01-P
